Aliskiren and dual therapy in type 2 diabetes mellitus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

1. THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2017
   Pooled it
2. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.Nature reviews. Nephrology · 2021
   Review
3. Renal and cerebral RAS interaction contributes to diabetic kidney disease.American journal of translational research · 2019
   Article
4. The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes.Diabetes care · 2012
   Article
5. Management of Diabetic Nephropathy in the Elderly: Special Considerations.Journal of nephrology & therapeutics · 2012
   Article
6. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Journal of general internal medicine · 2012
   Review
7. Risk for ESRD in type 1 diabetes remains high despite renoprotection.Journal of the American Society of Nephrology : JASN · 2011
   Article
8. Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?Nature clinical practice. Endocrinology & metabolism · 2009
   Article
9. Redox control of renal function and hypertension.Antioxidants & redox signaling · 2008
   Review

Corrections and comments

• Comment on
  Aliskiren combined with losartan in type 2 diabetes and nephropathy.2008

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as